Table VII.
Prevalence of patients who were treated with high doses of statins and remained with high post-therapy levels of LDL-C in subpopulations defined by CV risk and statin monotherapy or statin-ezetimibe combination therapy. The thresholds for the LDL-C concentrations were adopted from the current Polish statement [20] and current European guidelines [21]
| Type of treatment used | LDL-C concentration at last follow-up visit [mmol/l] | All patients N (%) | High cardiovascular risk patients N (%) | Very high cardiovascular risk patients N (%) |
|---|---|---|---|---|
| Overall population | > 4.1* | 31 (14.0) | 24 (13.6) | 7 (15.6) |
| > 5.2** | 9 (4.1) | 9 (5.1) | 0 (0) | |
| High doses of statin in monotherapy | > 4.1* | 5 (12.8) | 3 (10.7) | 2 (18.2) |
| > 5.2** | 2 (5.1) | 2 (7.1) | 0 (0) | |
| High doses of statins in combination with ezetimibe | > 4.1* | 7 (9.9) | 4 (7.7) | 3 (15.8) |
| > 5.2** | 1 (1.4) | 1 (1.9) | 0 (0) |